Autoimmune diseases are often precipitated by viral infections. Yet our current understanding fails to explain how viruses trigger organ-specific autoimmunity despite thymic tolerance extending to many nonlymphohematopoietic self antigens. Additionally, a key epidemiological finding needs to be explained: In genetically susceptible individuals, early childhood infections seem to predispose them to multiple sclerosis (MS) or type 1 diabetes years or even decades before clinical onset. In the present work, we show that the innate immune system of neonatal mice was sufficient to eliminate an attenuated lymphocytic choriomeningitis virus (LCMV) from most tissues except for the CNS, where the virus persisted in neurons (predisposing virus). Virus-specific cytotoxic T cells (CTLs) were neither deleted nor sufficiently primed to cause disease, but they were efficiently triggered in adulthood upon WT LCMV infection (precipitating virus). This defined sequence of viral infections caused severe CNS inflammation that was histomorphologically reminiscent of rasmussen encephalitis, a fatal human autoimmune disease. Yet disease in mice was mediated by antiviral CTLs targeting an epitope shared by the precipitating virus and the predisposing virus persisting in neurons (déjà vu). Thus the concept of “viral déjà vu” demonstrates how 2 related but independently encountered viral infections can cause organ-specific immune disease without molecular mimicry of self and without breaking self tolerance.
Autoimmune diseases are often precipitated by viral infections. Yet our current understanding fails to explain how viruses trigger organ-specific autoimmunity despite thymic tolerance extending to many nonlymphohematopoietic self antigens. Additionally, a key epidemiological finding needs to be explained: In genetically susceptible individuals, early childhood infections seem to predispose them to multiple sclerosis (MS) or type 1 diabetes years or even decades before clinical onset. In the present work, we show that the innate immune system of neonatal mice was sufficient to eliminate an attenuated lymphocytic choriomeningitis virus (LCMV) from most tissues except for the CNS, where the virus persisted in neurons (predisposing virus). Virus-specific cytotoxic T cells (CTLs) were neither deleted nor sufficiently primed to cause disease, but they were efficiently triggered in adulthood upon WT LCMV infection (precipitating virus). This defined sequence of viral infections caused severe CNS inflammation that was histomorphologically reminiscent of rasmussen encephalitis, a fatal human autoimmune disease. Yet disease in mice was mediated by antiviral CTLs targeting an epitope shared by the precipitating virus and the predisposing virus persisting in neurons (déjà vu). Thus the concept of “viral déjà vu” demonstrates how 2 related but independently encountered viral infections can cause organ-specific immune disease without molecular mimicry of self and without breaking self tolerance.

**Introduction**

The infectious hypothesis for MS dates back to the nineteenth century (1). Since then, it has been supported by a large number of epidemiological observations (2), of which only few can be mentioned here: Latitude-associated differences in prevalence (2) and relatively low concordance rates between homozygotic twins (3) demonstrate a strong impact of environmental factors besides an undisputed role of the genetic context (4). According to migration studies, environmental conditioning encountered before the age of 15 confers greater susceptibility to disease (2). Yet onset of disease occurs commonly only after years or even decades and often simultaneously with viral infections (5, 6). A number of parallel observations including twin discordance rates (7) have been made for type 1 diabetes (T1D). Congenital rubella is a classic though rare example of virus-induced diabetes in humans (8). Moreover, a role for infectious agents has long been suggested by the presence of coxsackie virus–specific serum antibodies in prediabetic and new-onset T1D patients (9, 10). This was later supported by the observation that a coxsackie virus isolated from a diabetic patient’s pancreas transferred the disease to animals (11). More recently, the findings of seasonality of birth in certain high-prevalence cohorts (12) and elevated enterovirus-specific antibodies in pregnant mothers of children who subsequently develop T1D (10, 13) suggest that, similar to MS, environmental factors in fetal or early neonatal life confer genetically susceptible individuals (14) with predisposition to disease. The finding of a similar seasonal peak in disease onset lent support to the hypothesis that an independent infectious event precipitates disease (15), potentially after a long phase of subclinical progression (10, 16).

Another autoimmune syndrome that often follows an infectious episode is rasmussen encephalitis (RE; ref. 17). RE is manifested by epileptic seizures that are refractory to antiepileptic drugs and ultimately require the surgical removal of affected brain regions. The histological picture of affected brain regions is dominated by infiltrating CD8+ T lymphocytes that are often found in direct contact with neurons (18). Infiltrating CTLs exhibit biased receptor usage indicative of an antigen-specific process and currently represent the most likely mediators of RE (19). The histomorphological similarity to viral encephalitis had long ago fostered speculations about an underlying viral pathogenesis in RE (17). Over time enteroviruses, Epstein-Barr virus, herpes simplex virus 1, and also cytomegalovirus have been detected in affected brain tissue (19). Final proof for an infectious culprit is, however, missing, as it is for all the other autoimmune diseases with a suspected viral pathogenesis.

Experimentally, a number of concepts could explain virus-induced, organ-specific, T cell–mediated diseases. They include molecular mimicry of self structures by pathogens (20), T cell epitope spreading to tissue-specific self epitopes upon virus-mediated tissue destruction (21) and bystander activation of autoreactive T cells (22). Furthermore, autoreactive T cells induced by molecular mimicry of self or in a bystander fashion may require subsequent triggering by non-specific inflammatory stimuli to cause an autoaggressive disorder (fertile field hypothesis; ref. 23). Models for these not mutually exclusive mechanisms have provided key insights into the molecular mechanisms of immune-mediated tissue damage and will undoubtedly help to develop therapies aimed at interfering with these processes (24). It is still debated, however, to what extent these models recreate the pathogenesis of human autoimmune diseases (25). Importantly,

Nonstandard abbreviations used: ARM, LCMVwt strain Armstrong; GP, glycoprotein; i.e., intracerbral(vy); INDG, GP of VSV serotype Indiana; LCMV, lymphocytic chorionominengitis virus; NP, nucleoprotein; NP396, immunodominant H-2Dd–restricted, LCMV-NP–derived CTL epitope; r, recombinant; RE, rasmussen encephalitis; rLCMV/INDG, rLCMV expressing INDG instead of LCMV-GP; rVSV/LCMV-GP, rVSV expressing LCMV-GP instead of INDG; T1D, type 1 diabetes; VSV, vesicular stomatitis virus.

**Conflict of interest:** The authors have declared that no conflict of interest exists.

**Citation for this article:** J Clin Invest. 116:1254–1263 (2006). doi:10.1172/JCI27372.
The Journal of Clinical Investigation

Inefficient induction of virus-specific CD8+ T cells in rLCMV/INDG carriers. (A) Neonatal and adult C57BL/6 mice were infected with rLCMV/INDG i.c. or were left uninfected. On days 7 and 50, NP396-specific CD8+ T cells in the spleen (day 7) and blood (day 50) were enumerated by flow cytometry using MHC class I tetramers (H-2Db/NP396). Numbers indicate percentages of NP396-specific CD8+ cells within the CD8+ T cell compartment (mean ± SD of 3–4 mice). (B) Neonatal (rectangles) or adult (triangles) C57BL/6 mice were infected with rLCMV/INDG i.c. or were left uninfected (circles). Mice were sacrificed 7 and 50 days later, and NP396-specific CTL activity was determined after in vitro restimulation of splenocytes in the presence (filled symbols) or absence (open symbols) of rIL-2. Shown are mean ± SEM of 3–4 mice per group. Cultures with rIL-2 were not significantly different from cultures without rIL-2 (not shown). (C) Mice were challenged with ARM i.v. 50 days after infection as described above. The frequency of NP396-specific CD8+ T cells in blood was measured using MHC class I tetramers. Values differing significantly from those of ARM-challenged mice without prior rLCMV/INDG infection (circles) are indicated. (D) rLCMV/INDG carrier mice (50 days old) and naive adult control mice were challenged with ARM i.v. Seven days later mice were sacrificed, and the NP396-specific primary ex vivo CTL activity of splenocytes was measured. Shown are mean ± SEM of 3 mice. Specific lytic activity of naive control splenocytes was <3% (not shown). Most panels are representative of 2 similar experiments. *P < 0.05; **P < 0.01.

Results

Antiviral CD8+ T cells of rLCMV/INDG carriers are neither deleted nor efficiently induced. First we tested whether neonatal i.c. infection with rLCMV/INDG elicits a CD8+ T cell response against the immunodominant H-2Db-restricted, LCMV-nucleoprotein–derived (LCMV-NP–derived) CTL epitope NP396. Measurements with MHC class I tetramers were carried out 7 and 50 days after infection and showed specific T cell frequencies around the detection limit (Figure 1A and data not shown). In some experiments, a slight elevation over background levels appeared as a trend that was not statistically significant. CTL assays after in vitro restimulation with peptide in the presence or absence of exogenous rIL-2 yielded analogous results (Figure 1B). Together these findings rendered the presence of a substantial population of NP396-specific CD8+ T cells unlikely. As positive control, we inoculated adult mice i.c. with the same dose. Unlike LCMVwt strains (32), adult i.c. infection with rLCMV/INDG did not result in lethal CD8+ T cell–mediated choriomeningitis. Rather, rLCMV/INDG was cleared from the brain in a clinically silent fashion (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI27372DS1) that was T cell dependent (D. Merker and D.D. Pinschwer, unpublished observations). At the peak of the response, approximately 4% of the circulating CD8+ T cells were NP396 specific, and long-lived CTL memory was induced (Figure 1, A and B, and data not shown), confirming our previous observation that rLCMV/INDG

mals induces a vigorous CTL response that mediates viral clearance and results in lifelong protective CTL memory.

We have described a genetically engineered recombinant LCMV (rLCMV) carrying the surface glycoprotein (GP) of vesicular stomatitis virus (VSV) serotype Indiana (INDG) instead of its own GP (rLCMV/INDG) (30). rLCMV/INDG exhibits attenuated growth in tissue culture (30, 31) but it has retained the ability of LCMVwt to establish carrier status in neonatally i.c. infected mice (rLCMV/INDG carrier mice; ref. 30). Experiments aimed at analyzing CTL reactivity to rLCMV/INDG in carrier mice have led us to what we believe to be novel insights on how altered parameters of virus-host balance during persistent infection can cause organ-specific immune disease independent of reactivity to self.

all these postulates rely on bona fide self-reactive T cells, but the need to break tolerance to self conflicts somewhat with the recent finding that thymic T cell tolerance extends to many tissue-specific self antigens (26). Moreover, it is still poorly understood how predisposition to disease is acquired during a phase of susceptibility in early childhood despite the lack of temporal association with disease onset (2, 10, 12, 13). We therefore reinvestigated immunological tolerance against neonatal viral infections (27, 28) as a putative link between early childhood infections and organ-specific immune diseases.

Intracerebral (i.c.) neonatal infection (~24 hours after birth) of mice with naturally occurring strains of lymphocytic choriomeningitis virus (LCMV; naturally occurring strain referred to as LCMVwt) is widely used to study viral persistence (27). Systemic infection involves the neonatal thymus (29) and results in central antiviral CD8+ T cell tolerance. This prevents cytotoxic T cell–mediated (CTL-mediated) disease in neonatally infected virus carriers and, together with noncytolytic behavior of LCMV in vivo, allows for lifelong viral persistence. In contrast, i.v. infection of adult ani-
was a potent trigger for CD8+ T cells of adult mice (31). Thus the response in newborn animals would have been in keeping with neonatal antiviral tolerance by clonal deletion. Yet our observations could also have reflected inefficient induction of the CD8+ T cell response as previously observed in other clinical and experimental settings of neonatal exposure to viral infection and foreign tissue, respectively (28, 33). To differentiate between these possibilities, we challenged 50-day-old rLCMV/INDG carriers, mice immunized as adults with rLCMV/INDG via the i.c. route (referred to as rLCMV-INDG–immune), and naive adult controls with the LCMVwt strain Armstrong (ARM) i.v. (Figure 1, C and D). Four days later, adult rLCMV/INDG–immune mice, but not carriers or previously naive controls, exhibited a recall response; however, by day 8, rLCMV/INDG carrier mice showed high frequencies of NP396-specific CD8+

Table 1

<table>
<thead>
<tr>
<th>Genotype of serum donor</th>
<th>rLCMV/INDG carrier serum</th>
<th>Cell culture–derived virus</th>
<th>No inoculation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype of serum donor</td>
<td>rLCMV/INDG carrier serum</td>
<td>Cell culture–derived virus</td>
<td>No inoculation</td>
</tr>
<tr>
<td>Genotype of serum donor</td>
<td>rLCMV/INDG carrier serum</td>
<td>Cell culture–derived virus</td>
<td>No inoculation</td>
</tr>
<tr>
<td>Genotype of serum donor</td>
<td>rLCMV/INDG carrier serum</td>
<td>Cell culture–derived virus</td>
<td>No inoculation</td>
</tr>
<tr>
<td>Genotype of serum donor</td>
<td>rLCMV/INDG carrier serum</td>
<td>Cell culture–derived virus</td>
<td>No inoculation</td>
</tr>
</tbody>
</table>

Groups of 3 C57BL/6 mice were inoculated i.c. either with serum of rLCMV/INDG carrier mice of A–/– RAG–/– or RAG–/– genotype or with cell culture-derived virus (positive control) or they were not inoculated (naive control). Four individual rLCMV/INDG carriers (neonatally infected) served as donors of serum. Infectivity of the 30-µl i.c. serum was assessed by tissue culture immunofocus assay, with a detection limit of 50 PFU/ml (~2 PFU/30 µl). Infectivity in cell culture–derived viral inocula was calculated based on the viral stock titer and the dilutions made. Seven days after inoculation, serum samples were collected and tested in neutralization assays. Titers were calculated as (–log2) of 40-fold prediluted serum. Seven days after inoculation, the frequency of NP396-specific CD8+ T cells in blood was determined by MHC class I tetramer staining. Analogous antibody and CTL response results were obtained on day 14 after inoculation (not shown).
T cells, ruling out deletion of the virus-specific CTL repertoire as observed after neonatal ARM infection (Figure 1C). Moreover, these cells were fully functional, as determined in a primary ex vivo CTL assay (Figure 1D). The rapidity of onset and the overall course of the CD8+ T cell response in rLCMV/INDG carrier mice was not significantly different from previously naive control mice, as assessed by repeated-measures ANOVA (Figure 1C). In rLCMV/INDG carrier mice, however, NP396-specific CD8+ T cell frequencies at days 8, 12, and 20 after ARM challenge were significantly higher than in previously naive mice (Figure 1C). This suggested prior induction of NP396-specific CD8+ T cells, albeit to such a low degree that they escaped detection in the experiments shown in Figure 1, A and B, and had only become apparent upon secondary infection with ARM. Yet viral challenge experiments failed to demonstrate protection by putative CD8+ memory T cells (Supplemental Figure 2), confirming that most rLCMV/INDG carrier mice had an NP396-specific CD8+ T cell repertoire that was neither deleted nor sufficiently induced to confer protective antiviral immunity.

**Innate immunity is sufficient to restrict rLCMV/INDG persistence to CNS neurons.** To understand how CD8+ precursor T cells could have been blinded to the persistent rLCMV/INDG infection in a way that they were neither deleted in the thymus nor efficiently induced in secondary lymphoid organs, we analyzed the viral distribution in the host. Unlike ARM carrier mice, viral RNA was found in brain but not in kidney, spleen, or thymus of C57BL/6 rLCMV/INDG carrier mice (Figure 2A; analogous findings in BALB/c and 129Sv mice not shown). The RAG−/− rLCMV/INDG carriers exhibited the same distribution, indicating that adaptive immune responses were not required for CNS restriction. Only in rLCMV/INDG carrier mice with a deletion of the type I IFN receptor gene in addition to deletion of the RAG gene (A−/−RAG−/− mice; ref. 34) was viral RNA found in all organs tested and the serum infectious (Figure 2A and Table 1). This was in accordance with the pantractive nature of INDG and indicated that CNS restriction of rLCMV/INDG in carrier mice was not due to viral receptor tropism but was a result of innate immune control outside the CNS. Experiments in type I IFN receptor–deficient but RAG-competent (A−/−) mice have shown that persistent infection with rLCMV/INDG was also restricted to the CNS (Supplemental Figure 3A), similar to WT mice, indicating that adaptive immune mechanisms could compensate for the lack of type I IFN effects. In support of this we found that the serum of A−/− rLCMV/INDG carriers exhibited INDG-specific neutralizing activity at a titer of approximately 1:10,000 (data not shown). This rendered rLCMV/INDG carrier A−/− mice resistant to challenge with VSV serotype Indiana (VSV-IND) at greater than 10,000 times the lethal dose, a well-established readout system for antibody-mediated protection (ref. 31 and Supplemental Figure 3B). To address the question of whether antibodies are necessary to prevent significant spillover of virus from the brain into the periphery of type I IFN receptor–competent mice, we performed serum transfer experiments. Inoculation i.c. of adult C57BL/6 mice with rLCMV/INDG represented a sensitive readout system for even low amounts of infectivity (–1 PFU) by eliciting vigorous B and T cell responses (Table 1). Yet the transfer of serum from RAG−/− rLCMV/INDG carriers i.c. into naive C57BL/6 mice failed to elicit a detectable antiviral CTL or antibody response, whereas A−/−RAG−/− serum was highly immunogenic (Table 1). An assessment of viral infectivity in the sera by immunofocus assay yielded analogous results, confirming that even in RAG−/− mice that lack antibodies, the persistently infected CNS released at best very little virus (Table 1). In support of this notion we found also that in B cell–deficient μMT mice, antiviral CTLs were no more efficiently induced than in C57BL/6 mice (Supplemental Figure 3C). Thus type I IFN–mediated containment of rLCMV/INDG within the CNS was a plausible explanation for why virus-specific CTLs of rLCMV/INDG carriers were neither clonally deleted nor efficiently induced prior to ARM challenge, but additional mechanisms could also be envisaged (see Discussion). Immunohistochemical analysis of brain and spinal cord (Figure 2B; for overview images, see Supplemental Figure 4) revealed that neurons of rLCMV/INDG carriers expressed viral antigen, while virus was undetectable in oligodendrocytes, astrocytes, endothelial cells, or microglia. Yet restriction to neurons as well as regional distribution of rLCMV/INDG within the CNS were unaltered in A−/−RAG−/− mice (Supplemental Figures 5 and 6). This indicated that unlike viral restriction to the CNS, neither adaptive immune control nor type I IFN signaling — rather other as-yet undefined mechanisms — were responsible for the observed virus distribution and cell tropism within the CNS.

**Viral déjà vu elicits CNS immune disease.** In the experiments shown in Figure 1C, we observed that ARM challenge of rLCMV/INDG carriers caused sudden weight loss and general malaise, while both control groups remained healthy. The disease started approximately 7 days after the second viral exposure, peaking around days 8–12 (Figure 3A). Behavioral analysis with a rotating rod (Figure 3B) revealed that motor coordination and balance were impaired, suggesting an underlying CNS process. The phenomenon was highly reproducible and required euthanasia of up to 50% of rLCMV/INDG carrier mice. Some variability in the severity of disease was, however, not surprising in the light of analogous findings with other models for CNS immune disease. In accordance with healthy appearance (30) and unimpaired motor func-
tion (Figure 3B), histological analysis of brain and spinal cord of rLCMV/INDG carriers prior to ARM i.v. challenge showed only background T cell infiltration (summarized in Figure 4C). Upon ARM challenge, however, dense and widespread inflammatory infiltrates were found within the gray matter of brain as well as spinal cord (Figure 4, A and C, and data not shown). Infiltrates in the 2 control groups were in the background range regardless of challenge with ARM. Thus clinical and histological disease correlated strictly with persistent LCMV antigen only in rLCMV/INDG carriers (predisposing virus) and with secondary ARM challenge (precipitating virus) of these mice (Figure 4, A and C, and data not shown).

Interestingly, the histological picture of this inflammatory process exhibited striking histomorphological similarities to human RE (compare Figure 4A with Figure 4B) (18). In both diseases the CNS infiltrate consisted largely of CD8+ T cells that appeared to be in contact with neurons. Yet the specificity of CD8+ T cells associated with gray matter neurons of RE patients (18) remains unknown and is widely assumed to be autoreactive. In our model, though, LCMV antigen–positive neurons of ARM-challenged rLCMV/INDG carriers were preferentially surrounded by T cells (Figure 4A). When counting T cells in direct contact with a neuron, 94 of 117 T cells (~80%) in 4 representative animals were associated with an LCMV antigen–positive neuron. Considering that less than 50% of all neurons were rLCMV/INDG infected, this suggested that T cells specifically recognized viral epitopes on infected neurons and argued against self reactivity as an underlying mechanism of disease. Nevertheless, this did not directly demonstrate the contribution of these cells to disease, nor could we rule out yet that nonspecific virus-induced inflammation rather than viral antigen attracted effector T cells to the site of rLCMV/INDG persistence.

Figure 4 T cell infiltration in the brains of ARM-challenged rLCMV/INDG carriers. (A) Neonatal and adult C57BL/6 mice were infected at day –50 with rLCMV/INDG i.c., resulting in rLCMV/INDG carriers and rLCMV/INDG–immune mice, respectively. On day 0, these animals and a control group of adult mice without LCMV/INDG infection were challenged with ARM i.v. Brain (top and center panels) and spinal cord sections (bottom panel) were prepared 8 days after ARM challenge and stained for LCMV-NP and CD3+ T cells. Representative images of 7–10 mice per group are shown. Scale bars: 500 µm (top); 100 µm (center); 20 µm (bottom). (B) Brain biopsy of a human patient with RE. A representative neuron surrounded by CD8+ T cells (brown) is shown. Scale bar: 20 µm. (C) C57BL/6 mice were infected with rLCMV/INDG as in A and sacrificed either immediately preceding ARM challenge 50 days later (groups I–III) or 8–12 days after ARM challenge (the peak of disease in rLCMV/INDG carriers; groups IV–VI) to determine the brain inflammatory index. Symbols represent individual mice from a total of 3 independent experiments; horizontal lines indicate means. Neonatally rLCMV/INDG-infected mice after ARM i.v. challenge (Group IV) exhibited dense T cell infiltration in brain, whereas the remaining groups were statistically indistinguishable from each other. Analogous results were also obtained for spinal cord (not shown). **P < 0.001 versus all other groups.
A single dominant specificity of antiviral CTL causes viral déjà vu disease. To experimentally address the question of how viral déjà vu precipitated CNS immune disease we considered that the CTL response to ARM predominantly targets the viral GP and NP proteins. Only the NP gene, not the GP gene, is shared between rLCMV/INDG persisting in brain and ARM precipitating disease (30). Thus, NP-specific but not LCMV-GP–specific CTLs should have been able to cause disease if indeed persisting rLCMV/INDG antigen represented the target of CNS-infiltrating CTLs. In contrast, bystander damage of rLCMV/INDG-infected neurons should not have occurred in a viral gene–specific manner. We therefore tested the hypothesis that NP396, the immunodominant H-2Dβ–restricted, NP-derived epitope, was the primary target of the pathogenic CTL response. For this purpose, rLCMV/INDG carrier mice were either rendered tolerant to NP396 by peptide treatment (35) or they were given diluent only as a control prior to ARM i.v. challenge. Tolerization reduced the ensuing response against NP396 (the major CTL epitope shared between rLCMV/INDG and ARM) to background levels, whereas the response to the immunodominant LCMV-GP–derived H-2Dβ–restricted CTL epitope GP33 (not shared by rLCMV/INDG) and to subdominant NP- and GP-derived epitopes remained unimpaired or were even enhanced (Figure 6A and data not shown). This latter effect was likely due to the absence of competing NP396-specific CTL (36). Unlike controls treated only with diluent, NP396-tolerized rLCMV/INDG carriers remained clinically healthy and exhibited no weight loss (Figure 6B). Motor coordination remained unimpaired apart from a transient, modest reduction around day 8 after challenge that failed to reach statistical significance (Figure 6C). Unlike in control mice, this slight dip was reversible by day 9–10 and in some experiments was also observed in previously naive mice infected with ARM i.v. (data not shown). Histological analysis at the peak of disease indicated that LCMV antigen levels were identical in both groups (Figure 6D). But compared with diluent-treated control mice, NP396 tolerization reduced T cell infiltrates in brain and spinal cord from 331 ± 155 to 10 ± 4 and from 250 ± 157 to 8 ± 3 cells/mm2 (mean ± SD; P < 0.01), respectively (Figure 6D and data not shown). Thus abrogation of CNS inflammation and clinical disease by NP396 tolerization demonstrated that the autoimmune-like disease in ARM-challenged rLCMV/INDG carriers was mediated by virus-specific (NP396) CTL. Taking into consideration that NP396 reactivity did not cause CNS inflammation in mice lacking viral antigen in neurons (e.g., in naive mice or in rLCMV/INDG–immune mice challenged with ARM; compare Figure 3 with Figure 4, A and B), abrogation of disease by NP396 tolerization excluded a viral mimic of self as a potential underlying mechanism. Therefore, the disease observed in i.v. ARM-challenged rLCMV/INDG carrier mice was due to the now efficient induction of NP396-specific CD8+ T cells that homed to the brain and targeted rLCMV/INDG in persistently infected neurons. These conclusions were independently corroborated in adoptive transfer experiments (see Supplemental Results and Supplemental Figure 7).

Secondary infection with an unrelated virus fails to elicit disease. Our experiments based on NP396 peptide tolerization (Figure 6) indicated that virally induced inflammation was insufficient — although likely necessary — to trigger inflammatory CNS disease in rLCMV/INDG carriers. To confirm that antigenic determinants shared between the persisting virus in CNS (rLCMV/INDG) and the acutely infecting virus in the periphery (ARM) represented a requirement for inflammatory CNS disease, rLCMV/INDG carriers were challenged either with ARM as positive control or with a genetically engineered rVSV expressing the LCMV-GP instead of INDG (rVSV/LCMV-GP; ref. 31). This virus therefore binds to the same cellular receptor as ARM, without however sharing antigenic determinants with rLCMV/INDG persisting in the CNS (31). Unlike ARM challenge, adult infection of rLCMV/INDG carriers with rVSV/LCMV-GP did not cause weight loss, impaired motor coordination, or T cell infiltration of the CNS (Figure 7). Analogous results were also obtained when vaccinia virus was used as a precipitating virus (data not shown). Thus virus-induced inflammation alone was insufficient to trigger CNS immune disease in rLCMV/INDG carriers.

**Discussion**

Viral déjà vu disease results from a defined chronology of antigenically related viral infections. ARM or rLCMV/INDG infection of naive mice did not cause disease, and rLCMV/INDG challenge of neona-
tally infected ARM carriers was clinically silent (data not shown), most likely due to antiviral CD8+ T cell tolerance (27, 28). Moreover, rLCMV/INDG persisted in the CNS of carriers at comparable levels for at least 100 days (as determined by immunohistochemistry; data not shown) and remained restricted to neurons. Yet disease was not observed in the absence of ARM challenge.

A schematic of the viral déjà vu pathogenetic mechanism is presented in Figure 8. Organ-restricted viral persistence may result from an infection encountered in neonatal life (33) or simultaneously with a second immunosuppressive infection (e.g., measles or herpesviruses; ref. 37). Under such circumstances, the virus may initially spread throughout the body but innate immune mechanisms such as type I IFNs, possibly aided by antibodies, may be sufficient to clear the virus from most tissues. Owing to an inefficient T cell response, virus may though persist in particular sites (predisposing virus). Neonatal rLCMV/INDG infection created a similar situation. It is well established that the majority of an i.c. inoculum is rapidly drained to the bloodstream (38), creating in essence a systemic infection with involvement of the CNS. This was reflected here in the antiviral antibody response of newborns (Supplemental Figure 3B and Supplemental Figure 8) and also in the potent CD8+ T cell response in adult i.c. infected mice (Figure 1). Under natural conditions of a systemic infection, viruses may profit from the immature blood-brain barrier of neonates to enter the CNS via the blood. Alternatively, they may access the CNS via peripheral nerves (analogous to rabies virus) or via the olfactory system (respiratory infections). Thus the initial route of neuroinvasion may determine a discrete site of immune disease triggered years or even decades later upon viral déjà vu. Preliminary data obtained with rLCMV/INDG indicate that in a small proportion of animals, vertical transmission or mucosal infection via the neonate’s nose can also result in persistent infection that is then restricted to the CNS (data not shown). Owing to the relatively low frequency of these events in our experimental system, however, these routes of infection could not be exploited for the present study.

The viral déjà vu model and transgenic mice with tissue-specific expression of a viral neo–self antigen (molecular mimicry; refs. 23, 24, 39) share a characteristic trait: In both cases, a viral infection can elicit T cell–mediated damage to specific organs. There are, however, fundamental differences between molecular mimicry and our viral déjà vu postulate that have wide-ranging implications:

First, molecular mimicry implies that similar epitopes are shared between a virus and the host (i.e., pathogen-host mimicry) and that virus-induced T cells therefore recognize and damage cells expressing self (23, 24, 39). In contrast, viral déjà vu is based on an epitope shared between 2 related viruses (i.e., pathogen-pathogen mimicry or simply antiviral cross-reactivity), representing a relatively fre-
quent finding (40). In this setting, tissue damage is therefore mediated by antiviral CTLs targeting viral non-self. This difference is important since CD8⁺ precursor T cells specific for bona fide self (including transgenic neo–self antigens) are potentially subject to autoimmune regulator–dependent (AIRE-dependent) mechanisms of thymic tolerance (26). In contrast, thymic medullary epithelial cells of rLCMV/INDG carriers lack the viral genetic information and cannot negatively select virus-specific CD8⁺ precursors. Hence, viral déjà vu — but not molecular mimicry — circumvents AIRE-mediated central tolerance mechanisms.

Second, persisting virus as a target of immune attack (viral déjà vu) offers entirely different options for prevention, treatment, and early diagnosis than does an immune disease targeting self (molecular mimicry). If specific predisposing viruses were known, the establishment of a persistent infection could likely be prevented by vaccination of the individuals themselves, of their environment (herd immunity), or specifically of their mothers in case of vertical transmission (10, 13). Moreover, healthy virus carriers at risk for viral déjà vu disease could be identified by molecular fingerprint analysis of the persisting virus. Unlike for self antigens, a persisting virus could then be eradicated by drug treatment reverting the predisposition to immune disease.

Third, the viral déjà vu mechanism offers an attractive explanation for the epidemiological observations linking predisposition to immune diseases with environmental factors in early childhood (2, 8, 10, 12, 13). Molecular mimicry may account for the association of some infections with onset of immune disease, and the fertile field hypothesis represents an attractive postulate to explain virally mediated predisposition separate from the onset of disease. Yet the association between young age and a predisposing event is best explained by the viral déjà vu mechanism linking immunological immaturity and viral persistence.

Peripheral tolerance represents a second cornerstone for prevention of self-destructive disease (41), and persisting rLCMV/INDG may benefit from similar mechanisms of peripheral T cell tolerance, as self antigens do. Inappropriate antigen presentation in the neonatal period of first rLCMV/INDG encounter is likely one of them (42). Later in life, relatively tight containment of rLCMV/INDG in the CNS (see Table 1) suggests clonal ignorance (41) of the inefficiently expanded antiviral T cell compartment, but additional mechanisms such as regulatory T cells may also be possible. Déjà vu with ARM, however, seems

Figure 7
Absence of inflammatory CNS disease in rLCMV/INDG carriers challenged with rVSV/LCMV-GP instead of ARM. rLCMV/INDG carriers (50 days old) were challenged either with ARM or with rVSV/LCMV-GP i.v. (A and B) Body weight (A) and running time on the rotating rod (B) were monitored at the indicated time points after ARM challenge. Shown are the mean ± SEM of 5 mice per group. *P < 0.05 compared with highest value prior to disease onset. (C) At the peak of disease in ARM-challenged animals (day 11), all mice were sacrificed, and the brain inflammatory index was determined. Symbols represent individual mice; horizontal lines indicate means. **P < 0.01.

Figure 8
Schematic interpretation of the viral déjà vu immunopathogenetic mechanism. (A) Summary of the infection protocol eliciting CNS disease; viral distribution is denoted by color. (B) Mechanistic interpretation. In neonates and in adults, a substantial fraction of the rLCMV/INDG i.c. inoculum reaches the systemic circulation (38). Viral infection of secondary lymphoid organs is abortive due to efficient type I IFN–dependent control, whereas CNS infection is productive. In neonates but not in adults, viral gene expression in secondary lymphoid organs coincides with reduced T cell responsiveness. Hence adult mice mount a protective virus-specific (NP396 and other epitopes) CD8⁺ T cell response that clears rLCMV/INDG from the CNS, while virus persists in the neonate’s neurons. The antiviral CD8⁺ T cell response in neonates is inefficient, but ARM infection 50 days later triggers a vigorous response of NP396-specific CTLs (epitope shared by rLCMV/INDG and ARM) that causes CNS disease when reaching persistently rLCMV/INDG-infected neurons. Adult primary rLCMV/INDG infection has been cleared from the CNS, and hence only neonatally rLCMV/INDG-infected mice develop disease.
to overrule them, likely by a combination of specific (i.e., TCR-delivered) and nonspecific stimuli of the viral infection (e.g., toll-like receptor signals).

Despite our demonstration that viral déjà vu mimicked organ-specific autoimmune in WT inbred mouse strains, this concept — just like the other postulates (20–23) — awaits formal testing and verification in human autoimmune diseases (25). Importantly, the similarity of viral déjà vu to RE at the histomorphological level does not allow for conclusions regarding the etiology of this disorder. Yet it shows that the morphological appearance leading to the classification of RE as autoimmune disease could just as well result from viral déjà vu operating independently of reactivity to self. Therefore the insights provided by our model may be pivotal for the interpretation of available clinical data on viral infections and autoimmune diseases (5, 6, 9, 10, 12, 13) and for the future design of clinical studies. Instead of serologic surrogate markers (5, 9, 10, 13), detailed genetic fingerprinting (6) in affected tissues may be needed to link autoimmune disorders to a causative viral variant persisting in an affected organ.

Human herpesvirus 6 may serve as an example: Subtype 6B with >95% seroprevalence worldwide (potential predisposing virus) persists in oligodendrocytes (43), whereas the rare subtype 6A is serologically indistinguishable but frequently found in the serum of MS patients with relapses (6) (potential precipitating virus). Accordingly, measurements of LCMV-NP–specific serum IgG failed to differentiate mice at risk for CNS immune disease (rLCMV/INDG carriers) from rLCMV/INDG–immune mice that were not at risk (Supplemental Figure 8). Similarly, antiviral serum IgG levels in mice with viral déjà vu disease were similar to those of healthy ARM-immune mice.

Finally, it is important to note that the concepts of molecular mimicry (20), epitope spreading (21), bystander damage (22), fertile field (23), and viral déjà vu are by no means mutually exclusive, and different mechanisms could even lead to clinically indistinguishable syndromes. What renders the viral déjà vu proposal particularly attractive is that it circumvents central T cell tolerance, that it may disclose new strategies for prevention, and that it can just as well result from viral déjà vu operating independently of reactivity to self. Therefore the insights provided by our model may be pivotal for the interpretation of available clinical data on viral infections and autoimmune diseases (5, 6, 9, 10, 12, 13) and for the future design of clinical studies. Instead of serologic surrogate markers (5, 9, 10, 13), detailed genetic fingerprinting (6) in affected tissues may be needed to link autoimmune disorders to a causative viral variant persisting in an affected organ.

Human herpesvirus 6 may serve as an example: Subtype 6B with >95% seroprevalence worldwide (potential predisposing virus) persists in oligodendrocytes (43), whereas the rare subtype 6A is serologically indistinguishable but frequently found in the serum of MS patients with relapses (6) (potential precipitating virus). Accordingly, measurements of LCMV-NP–specific serum IgG failed to differentiate mice at risk for CNS immune disease (rLCMV/INDG carriers) from rLCMV/INDG–immune mice that were not at risk (Supplemental Figure 8). Similarly, antiviral serum IgG levels in mice with viral déjà vu disease were similar to those of healthy ARM-immune mice.

Finally, it is important to note that the concepts of molecular mimicry (20), epitope spreading (21), bystander damage (22), fertile field (23), and viral déjà vu are by no means mutually exclusive, and different mechanisms could even lead to clinically indistinguishable syndromes. What renders the viral déjà vu proposal particularly attractive is that it circumvents central T cell tolerance, that it may disclose new strategies for prevention, and that it can readily explain the epidemiological evidence linking predisposition and precipitation of some organ-specific immune diseases to separate infections in distinct periods of life.

Methods

Virus, virus titrations, inoculations, and determination of neutralizing antibodies. Virus stocks were prepared, infectivity was quantified, and VSV neutralizing antibodies were determined as described previously (31). For i.c. inoculations, 3 × 10⁴ PFU (unless otherwise indicated) of ARM or rLCMV/INDG in a volume of 30 μl or 30 μl of serum were administered through the scull of the vertex using a 27-gauge needle. For i.v. infection, 2 × 10⁴ PFU ARM or 2 × 10⁴ PFU VSV/LCMV-GP in a volume of 200 μl were administered into the tail vein.

Mice. C57BL/6, RAG−/−, A−/−RAG−/− (34), and μMT mice (31) were used. RAG−/− and μMT mice were on a C57BL/6 background, whereas A−/−RAG−/− mice were on a mixed C57BL/6 × 129SvEV background. To exclude that the differential virus distribution in RAG−/− and A−/−RAG−/− mice (Figure 2A) was due to differences in the genetic background, 129SvEV and A−/− mice (on a 129SvEV background; ref. 34) were also tested and yielded analogous results as obtained with RAG−/− and C57BL/6 mice (Supplemental Figure 3A and data not shown). Experiments were approved and authorized by the Kantonales Veterinäramt Zürich (Zurich, Switzerland) in accordance with the Swiss law for animal protection.

Peptide tolerization. Mice were administered 200 μg NP396 peptide in incomplete Freund’s adjuvant (IFA) i.p. on days 9, 6, and 3 prior to ARM infection as described previously (35). Controls received diluent in IFA.

Human brain tissue. A human brain biopsy of a patient with RE was obtained from the collection of the Department of Neuropathology at the Georg-August-Universität. Its use for scientific purposes was in accordance with the guidelines of the institutional ethics committee. This study was approved by the ethics committee of the University of Goettingen (Goettingen, Germany).

RNA detection. Viral S segment (~3.4 kb) and NP mRNA (~1.8 kb) were detected by Northern hybridization as described previously (30).

Rotarod. Mice were placed on a rotating rod (Rotarod 7650; Ugo Basile Bioresearch Apparatus) constantly accelerating from 4 to 40 rounds per minute for a maximum of 300 seconds. Endurance time was monitored, and the values obtained in 3 trials per time point were averaged for further analysis.

Brain-extracted lymphocytes, CTL assays, and flow cytometry. Splenic single-cell suspensions and brain-extracted lymphocytes (44) were tested in primary ⁵¹Cr release assays as described previously (31, 44) or were restimulated for 5 days in vitro with NP396-pulsed (10⁶ M), irradiated splenocytes, in either the presence or the absence of 30 U/ml rIL-2. EL-4 cells coated with NP396 (10⁶ M) served as targets. Background killing on uncoated target cells was subtracted. Spontaneous release was 10.6–23.3%. Epitope-specific IFN-γ–producing and MHC class I tetramer–binding CD8⁺ T cells were detected by flow cytometric analysis as described previously (36). Allophycocyanin-conjugated anti-IFN-γ, FITC-conjugated anti-CD4, PE-conjugated anti-CD8β, and peridinin-chlorophyll protein–conjugated anti-B220 were purchased from BD Biosciences — Pharmingen. The frequency of IFN-γ ‘CD8’ or tetramer ‘CD8’ cells was calculated as a percent of CD8 B220 lymphocytes.

Histopathology. Tissues of transcardially perfused mice (4%) paraformaldehyde were embedded in paraffin. Upon inactivation of endogenous peroxidases (PBS/3% hydrogen peroxide) and blocking (PBS/10% FCS), sections were stained with primary antibodies: mouse anti-neuronal nuclei NeuN (Chemicon International), mouse anti-GFAP (astrocytes; Dako), mouse anti-CNPase (oligodendrocytes, myelin; Sternerberge Monclonal), rat anti-human CD3 (cross-reactive with murine T cells; Serotec), mouse anti-human CD8 (Dako), rat anti-MAC3 (microglia/macrophages; BD Biosciences — Pharmingen), rabbit anti-Iba-1 (microglia/macrophages; Wako Pure Chemical Industries Ltd.), FITC-labeled Tomato Lectin (blood vessels; Vector Laboratories), and rabbit anti-LCMVwt serum (referred to as LCMV-NP; ref. 29). Rat anti–mouse CD8 (BD Biosciences — Pharmingen) and goat anti-perforin (Santa Cruz Biotechnology Inc.) were costained on brain vessels; Vector Laboratories), and rabbit anti-LCMVwt serum (referred to as LCMV-NP; ref. 29). Rat anti–mouse CD8 (BD Biosciences — Pharmingen) and goat anti-perforin (Santa Cruz Biotechnology Inc.) were costained on brain vessels; Vector Laboratories), and rabbit anti-LCMVwt serum (referred to as LCMV-NP; ref. 29).

Histopathology. Tissues of transcardially perfused mice (4%) paraformaldehyde were embedded in paraffin. Upon inactivation of endogenous peroxidases (PBS/3% hydrogen peroxide) and blocking (PBS/10% FCS), sections were stained with primary antibodies: mouse anti-neuronal nuclei NeuN (Chemicon International), mouse anti-GFAP (astrocytes; Dako), mouse anti-CNPase (oligodendrocytes, myelin; Sternerberge Monclonal), rat anti-human CD3 (cross-reactive with murine T cells; Serotec), mouse anti-human CD8 (Dako), rat anti-MAC3 (microglia/macrophages; BD Biosciences — Pharmingen), rabbit anti-Iba-1 (microglia/macrophages; Wako Pure Chemical Industries Ltd.), FITC-labeled Tomato Lectin (blood vessels; Vector Laboratories), and rabbit anti-LCMVwt serum (referred to as LCMV-NP; ref. 29). Rat anti–mouse CD8 (BD Biosciences — Pharmingen) and goat anti-perforin (Santa Cruz Biotechnology Inc.) were costained on brain vessels; Vector Laboratories), and rabbit anti-LCMVwt serum (referred to as LCMV-NP; ref. 29).

Acknowledgments
We are indebted to P. Aichele, F. Chisari, W. Fierz, N. Harris, J. Hausmann, H. Hengartner, M. Kerschensteiner, M. Loehning, C. Stadelmann, P. Staehehi, and H. Welz for helpful discussions and to B. Maruschaek and M. Schendensack for expert technical assistance. D. Merkler was supported by the Gemeinnützige Hertz Stiftung. This work was supported by grant 3100A0-104067/1 of the Swiss National Science Foundation (to D.D. Pinschewer) and by the Kanton of Zürich.

Received for publication November 9, 2005, and accepted in revised form February 14, 2006.

Address correspondence to: Daniel D. Pinschewer, Institute of Experimental Immunology, Department of Pathology, University Hospital of Zürich, Schmelzbergstrasse 12, 8091 Zürich, Switzerland. Phone: 41-1-2552989; Fax: 41-1-2554440; E-mail: pinschi@pathol.unizh.ch.